The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | An overview of risk- and response-adapted strategies for stage 3 NSCLC
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, gives an overview of risk- and response-adapted strategies for stage 3 non-small cell lung cancer (NSCLC). Baseline risk factors should be assessed to stratify patients and determine radiotherapy dose and volume. PET CT imaging can also be used to determine which patients can undergo treatment de-escalation. However, challenges remain in determining the optimal treatment strategy due to the heterogenous nature of the tumors. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
